Senti Biosciences (SNTI) Stock Price, News & Analysis

Company Overview

Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Key Stats

• Today's Range: $1.57 to $1.66
• 50-Day Range: $1.48 to $2.86
• 52-Week Range: $1.46 to $16.94
• Volume: 69,690 shs
• Average Volume: 173,317 shs
• Market Capitalization: $43.03 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.50
• Consensus Rating: Buy

Senti Biosciences Stock Analysis - MarketRank™

Senti Biosciences scored higher than 59% of companies evaluated by MarketBeat, and ranked 451st out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Senti Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Senti Biosciences has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Senti Biosciences are expected to grow in the coming year, from ($14.54) to ($1.88) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Senti Biosciences is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Senti Biosciences is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Senti Biosciences has a P/B Ratio of 1.75. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.49% of the float of Senti Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Senti Biosciences has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Senti Biosciences has recently decreased by 57.43%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Senti Biosciences does not currently pay a dividend.

Dividend Growth

Senti Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.49% of the float of Senti Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Senti Biosciences has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Senti Biosciences has recently decreased by 57.43%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.67

News Sentiment

Senti Biosciences has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Senti Biosciences this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for SNTI on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Senti Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.12% of the stock of Senti Biosciences is held by insiders.

Percentage Held by Institutions

Only 25.73% of the stock of Senti Biosciences is held by institutions.

SNTI Stock Analysis - Frequently Asked Questions

How have SNTI shares performed this year?

Senti Biosciences' stock was trading at $3.51 at the beginning of the year. Since then, SNTI shares have decreased by 53.1% and is now trading at $1.6450.

How were Senti Biosciences' earnings last quarter?

Senti Biosciences, Inc. (NASDAQ:SNTI) released its quarterly earnings data on Thursday, August, 7th. The company reported ($0.56) EPS for the quarter, beating analysts' consensus estimates of ($0.58) by $0.02. The business earned $0.50 million during the quarter, compared to the consensus estimate of $1.30 million.

When did Senti Biosciences' stock split?

Senti Biosciences's stock reverse split on the morning of Thursday, July 18th 2024.The 1-10 reverse split was announced on Thursday, July 18th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 18th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Who are Senti Biosciences' major shareholders?

Senti Biosciences' top institutional shareholders include Armistice Capital LLC (3.41%) and Geode Capital Management LLC (0.56%).
View institutional ownership trends.

How do I buy shares of Senti Biosciences?

Shares of SNTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Senti Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Senti Biosciences investors own include NVIDIA (NVDA), PayPal (PYPL), Meta Platforms (META), Pfizer (PFE), Advanced Micro Devices (AMD), Coinbase Global (COIN) and SoFi Technologies (SOFI).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 8/22/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SNTI
• CIK: 1854270
• Web: www.sentibio.com
• Phone: 650-239-2030
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Senti Biosciences: $8.50
• High Price Target: $12.00
• Low Price Target: $5.00
• Potential Upside/Downside: +434.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($8.95)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$52.79 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -223.98%
• Return on Assets: -76.02%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.26
• Quick Ratio: 3.26

Sales & Book Value

• Annual Sales: $2.56 million
• Price / Sales: 16.25
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.94 per share
• Price / Book: 1.69

Miscellaneous

• Outstanding Shares: 26,160,000
• Free Float: 25,344,000
• Market Cap: $41.59 million
• Optionable: Not Optionable
• Beta: 2.07